SCHEMBL12847641

SCHEMBL12847641

CCN1CC2(CCN(C)CC2)c2cc(Cl)ccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.47
HDAC1 Q13547 3/20 0.41
HDAC6 Q9UBN7 3/20 0.41
POLB P06746 2/20 0.39
OPRM1 P35372 3/20 0.36
SIGMAR1 Q99720 2/20 0.36
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
GRIN3A Q8TCU5 1/20 0.36
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
PAK1 Q13153 1/20 0.35
PKN1 Q16512 1/20 0.35
KCNK2 O95069 1/20 0.34
GRIA1 P42261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12847311 0.93 NOTUM (0.43) NOTUMHDAC1HDAC6POLBOPRM1
SCHEMBL12847359 0.86 NOTUM (0.45) NOTUMHDAC1HDAC6OPRM1SIGMAR1
SCHEMBL12847362 0.85 NOTUM (0.44) NOTUMHDAC1HDAC6OPRM1SIGMAR1
SCHEMBL14791762 0.84 SIGMAR1 (0.45) NOTUMHDAC1HDAC6OPRM1SIGMAR1
SCHEMBL17771738 0.84 NOTUM (0.52) NOTUMHDAC1HDAC6POLBOPRM1
SCHEMBL12847355 0.83 AKT1 (0.47) NOTUMHDAC1HDAC6HTR2AHTR2C
SCHEMBL12847725 0.82 NOTUM (0.41) NOTUMOPRM1SIGMAR1
SCHEMBL12847373 0.80 NOTUM (0.38) NOTUMHDAC1HDAC6OPRM1SIGMAR1
SCHEMBL13227804 0.80 HDAC1 (0.56) NOTUMHDAC1HDAC6OPRM1SIGMAR1
SCHEMBL12847329 0.79 SIGMAR1 (0.52) HDAC1HDAC6OPRM1SIGMAR1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130072500-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2013-03-21 US disclosed
US-8324221-B2 Pyrimidyl cyclopentanes as Akt protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-12-04 US disclosed
US-20110053959-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053959-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, PIK3CA NOTUM 2711/4885HDAC1 1919/4885HDAC6 1578/4885
US-20130072500-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS PIK3CA, AKT1, AKT2 NOTUM 2603/4885HDAC1 2110/4885HDAC6 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.